AJ1-11095 is a first-in-class Type II JAK2 inhibitor currently in a Phase 1 study for the treatment of patients with ...

Shares are up 7% in trading today, after Geron announced a strategic restructuring to "position the company for long-term ...

Incyte Announces New Positive Data for INCA033989, its First-In-Class mutCALR-Targeted Monoclonal Antibody, in Patients with ...

Beyond blood cancers, GT Biopharma is developing GTB-5550, which targets B7H3, a protein commonly found across various solid tumor types including breast, lung, ovarian, pancreatic, bladder, and ...

Data were shared at the 67th Annual Meeting of the American Society of Hematology (ASH) ORLANDO, Fla.--(BUSINESS WIRE)--December 8, 2025-- Opna Bio, ...

Incyte ( INCY) on Sunday said the U.S. Food and Drug Administration has granted Breakthrough Therapy designation to ...

Onctura initiates phase I/II trial of roginolisib in patients with myelofibrosis who are no longer responding to JAK inhibition: Geneva, Switzerland Friday, December 5, 2025, 15: ...

Orca Bio, a late-stage biotechnology company committed to transforming the lives of patients through high-precision cell therapy, today announced positive new data from its pipeline of allogeneic ...

Hemab Therapeutics, a clinical-stage biotechnology company developing novel prophylactic therapeutics for serious, underserved bleeding and thrombotic disorders, today announced positive results from ...

New investigational data from Phase 1/2 study of enzomenib (DSP-5336) in patients with relapsed/refractory acute myeloid leukemia (AML) show clinical ...

Standard-of-care treatment with Janus kinase inhibitor monotherapy improves splenomegaly and symptom burden but provides ...

For years, Mary considered herself pretty active. She used to play raquetball, swim, and participated in whitewater rafting down North California's rivers. Even when she wasn’t outdoors, she was busy ...